NIPH Clinical Trials Search

JAPANESE
国立保健医療科学院
JAPIC ID: JapicCTI-111451

Registered date:

Basic Information

Recruitment status
Health condition(s) or Problem(s) studiedInfluenza H5N1 prevention
Date of first enrollment
Target sample size
Countries of recruitment
Study typeINTERVENTIONAL
Intervention(s)Intervention name : KD-295 Dosage And administration of the intervention : Administer 0.25 mL or 0.5 mL of KD-295 by intramuscular injection in the extensor surface of the upper arm twice at an interval of 21 days (±2 days), alternating injection sites between the left and the right arms. Control intervention name : null

Outcome(s)

Primary Outcomenull
Secondary Outcomenull

Key inclusion & exclusion criteria

Age minimum20
Age maximum40
GenderMale
Include criteria(1) Subjects who are healthy adult males aged between 20 and 40 inclusive at the time of obtaining informed consent. (2) Subjects who are judged as eligible healthy adults for this clinical study by the principal investigator or subinvestigator based on the screening results. (3) Subjects who are able to give written informed consent, follow compliance rules while participating in this clinical study, receive medical examination and testing described in this protocol and report symptoms and other signs.
Exclude criteria

Related Information

Contact

public contact
Name The Chemo-Sero-Therapeutic Research Institute Development Coordination D(continued to "Affiliation")
Address ikai-ctinfo@kaketsuken.or.jp
Telephone
E-mail
Affiliation ivision Clinical Development Department
scientific contact
Name
Address
Telephone
E-mail
Affiliation